EDIT vs. RGNX, ADVM, BLUE, CLLS, SGMO, VRNA, EVO, NAMS, KURA, and AVDL
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include REGENXBIO (RGNX), Adverum Biotechnologies (ADVM), bluebird bio (BLUE), Cellectis (CLLS), Sangamo Therapeutics (SGMO), Verona Pharma (VRNA), Evotec (EVO), NewAmsterdam Pharma (NAMS), Kura Oncology (KURA), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "medical" sector.
Editas Medicine (NASDAQ:EDIT) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 1.9% of Editas Medicine shares are held by insiders. Comparatively, 13.1% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Editas Medicine has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
REGENXBIO received 124 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 65.64% of users gave REGENXBIO an outperform vote while only 53.64% of users gave Editas Medicine an outperform vote.
In the previous week, Editas Medicine had 2 more articles in the media than REGENXBIO. MarketBeat recorded 9 mentions for Editas Medicine and 7 mentions for REGENXBIO. Editas Medicine's average media sentiment score of 0.88 beat REGENXBIO's score of 0.38 indicating that Editas Medicine is being referred to more favorably in the media.
Editas Medicine has a net margin of -239.36% compared to REGENXBIO's net margin of -299.96%. Editas Medicine's return on equity of -47.34% beat REGENXBIO's return on equity.
Editas Medicine presently has a consensus target price of $12.90, suggesting a potential upside of 128.32%. REGENXBIO has a consensus target price of $38.58, suggesting a potential upside of 169.25%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts plainly believe REGENXBIO is more favorable than Editas Medicine.
Editas Medicine has higher earnings, but lower revenue than REGENXBIO. Editas Medicine is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Summary
REGENXBIO beats Editas Medicine on 10 of the 18 factors compared between the two stocks.
Get Editas Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Editas Medicine Competitors List
Related Companies and Tools
